Aptose Biosciences (APTO) said Monday that it has regained compliance with Nasdaq's minimum bid price requirement.
The company said it received a written notice for the compliance from the stock exchange on Friday after having a closing bid price of $1 or greater for 10 consecutive business days.
Aptose also said it is not in compliance with the $2.5 million stockholders' equity requirement of Nasdaq and is operating under an exception granted by the hearing panel of the stock exchange, which allows for additional time to regain compliance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.